Latest Quote @ Wed May 5 04:05:06 (15 min delayed)
Last Day's Data
SurModics, Inc. provides surface modification and drug delivery technologies for the healthcare industry. It operates in three segments: the Drug Delivery, the Hydrophilic and Other, and the Diagnostics. The Drug Delivery segment contains the Drug Delivery business unit, which offers technologies to site specific delivery of drugs; and the Ophthalmology division, which offers treatment for eye diseases, such as age-related macular degeneration and diabetic macular edema. The Hydrophilic and Other segment contains the Hydrophilic Technologies business unit, which focuses on enhancing medical devices with lubricious coatings; Regenerative Technologies business unit, which develops platforms to augment or replace tissue/organ function or to modify medical devices to facilitate tissue/organ recovery through natural repair mechanisms; and Orthopedics business unit, which offers solutions for orthopedics patients. The Diagnostics segment contains the Diagnostics and Drug Discovery business unit, which includes genomics slide technologies, stabilization products for immunoassay diagnostics tests, in vitro diagnostic format technology, and develops synthetic cell culture products. It offers PhotoLink surface modification coatings and drug delivery polymer matrices. The company provides polymer coatings for drug-eluting stents, lubricious coatings, and cell encapsulation technology for islet cell implantation. It also offers chemical reagents used in the coating process, as well as coated glass slides and stabilization products. The company serves medical device, pharmaceutical, and life science companies, as well as development stage companies. Its technologies and products are marketed through direct sales force worldwide. The company, formerly known as BSI Corporation, was founded in 1979 and changed its name to SurModics, Inc. in 1997. SurModics is headquartered in Eden Prairie, Minnesota.